Eustoma Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-01-2025
- Paid Up Capital ₹ 0.10 M
as on 03-01-2025
- Company Age 11 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -2.01%
(FY 2020)
- Profit -40.10%
(FY 2020)
- Ebitda -40.10%
(FY 2020)
- Net Worth 4.95%
(FY 2020)
- Total Assets -12.53%
(FY 2020)
About Eustoma Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dinesh Kumar and Ravi Manglani serve as directors at the Company.
- CIN/LLPIN
U24233MP2013PTC030121
- Company No.
030121
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Eustoma Laboratories Private Limited offer?
Eustoma Laboratories Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Pre & Probiotic Capsule, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Cardiovascular Drugs & Medication, Kidney Drugs, Multivitamin Syrup & Drops, Arthritic Drugs.
Who are the key members and board of directors at Eustoma Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Kumar  | Director | 26-Feb-2013 | Current |
| Ravi Manglani | Director | 26-Feb-2013 | Current |
Financial Performance of Eustoma Laboratories.
Eustoma Laboratories Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 2.01% decrease. The company also saw a substantial fall in profitability, with a 40.1% decrease in profit. The company's net worth moved up by a moderate rise of 4.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eustoma Laboratories?
In 2020, Eustoma Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eustoma Laboratories?
Unlock and access historical data on people associated with Eustoma Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eustoma Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eustoma Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
